1 February 2018 - The February 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The February issue of the Schedule includes a number of minor new/revised listings:

• Glycomacropeptide with long chain polyunsatutared fatty acids and docosahexaenoic acid and low in phenylalanine (PKU Sphere 15) - new formulation
  
• Lenalidomide (Revlimid) - restriction change
  
• Ocrelizumab (Ocrevus) - new medicine
  
• Pomalidomide (Pomalyst) - restriction change
• Raltegravir potassium (Isentress) - new formulation
  

Read Summary of Changes